These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36905966)

  • 21.
    Nord JA; Wynia-Smith SL; Gehant AL; Jones Lipinski RA; Naatz A; Rioja I; Prinjha RK; Corbett JA; Smith BC
    Front Endocrinol (Lausanne); 2022; 13():923925. PubMed ID: 36176467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
    Yang CY; Qin C; Bai L; Wang S
    Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.
    Yu S; Zhang Y; Yang J; Xu H; Lan S; Zhao B; Luo M; Ma X; Zhang H; Wang S; Shen H; Zhang Y; Xu Y; Li R
    Eur J Med Chem; 2024 Jan; 263():115924. PubMed ID: 37992518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
    Cai M; Dong J; Li H; Qin JJ
    Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
    Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Y06014 is a selective BET inhibitor for the treatment of prostate cancer.
    Wu TB; Xiang QP; Wang C; Wu C; Zhang C; Zhang MF; Liu ZX; Zhang Y; Xiao LJ; Xu Y
    Acta Pharmacol Sin; 2021 Dec; 42(12):2120-2131. PubMed ID: 33654218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
    Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
    Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
    Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
    Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
    Carrasco K; Montersino C; Derviaux C; Saez-Ayala M; Hoffer L; Restouin A; Castellano R; Casassa J; Roche P; Pasquier E; Combes S; Morelli X; Collette Y; Betzi S
    J Med Chem; 2022 Apr; 65(7):5660-5674. PubMed ID: 35348328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
    Sato M; Kondo T; Kohno Y; Seto S
    Bioorg Med Chem; 2021 Mar; 34():116015. PubMed ID: 33549905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.